|
Tick tock
|
4
|
Resverlogix Corp.
|
Aug 11, 2017 11:22AM
|
|
Tick tock
|
5
|
Resverlogix Corp.
|
Dec 11, 2018 10:43AM
|
|
Thursday, Friday and then hello September top-line?
|
9
|
Resverlogix Corp.
|
Aug 29, 2019 09:53AM
|
|
Three Nature Medicine Articles on BET inhibitors and Prostate Cancer
|
6
|
Zenith Epigenetics
|
Aug 15, 2017 10:42AM
|
|
Third Eye, AHA, US Listing
|
8
|
Resverlogix Corp.
|
Sep 08, 2019 08:35AM
|
|
Therapeutic Twitter Thread
|
9
|
Resverlogix Corp.
|
Nov 17, 2019 09:54AM
|
|
The waiting game.....
|
5
|
Resverlogix Corp.
|
Jan 11, 2019 11:09AM
|
|
The thread has been killed
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 03:25PM
|
|
The therapeutic potential of BRD4 in cardiovascular disease
|
7
|
Resverlogix Corp.
|
May 20, 2020 08:10AM
|
|
The synergy of rosuvastatin (Crestor) with apabetalone
|
12
|
Resverlogix Corp.
|
Oct 03, 2019 08:23AM
|
|
The significance of the SSRA
|
6
|
Resverlogix Corp.
|
Jun 19, 2018 01:03PM
|
|
The Seven Deadly Sins of Biotech Investing
|
|
Resverlogix Corp.
|
Dec 01, 2015 03:59PM
|
|
The scariest thing for a clinical trial......
|
2
|
Resverlogix Corp.
|
Oct 31, 2018 07:24PM
|
|
The runway is clear....
|
5
|
Resverlogix Corp.
|
Dec 05, 2018 04:13PM
|
|
The new competitors: SGLT2 inhibitors and GLP-1 Receptor Agonists
|
6
|
Resverlogix Corp.
|
Jun 13, 2016 11:43PM
|
|
The importance of sub-group analyses
|
6
|
Resverlogix Corp.
|
Dec 18, 2018 05:18PM
|
|
The HDL hypothesis lives on
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 07:50PM
|
|
The good, the bad and the ugly, part 2
|
5
|
Resverlogix Corp.
|
May 24, 2018 08:33PM
|
|
The glucose effect?
|
6
|
Resverlogix Corp.
|
Feb 21, 2019 01:34PM
|
|
The final events.....
|
6
|
Resverlogix Corp.
|
Jan 25, 2019 10:48AM
|
